Phil and Stephen continue their discussion with Dr. Aubrey de Grey, reviewing some of the very encouraging life extension research currently taking place
- How does the treatment of other conditions (cancer, diabetes, obesity, heart disease, etc) ultimately contribute to the first generation of anti-aging medicine?
- Will devices such as those created for the Qualcomm Tricorder X Prize be a game-changer for treating aging?
- What role will CRISPR technology play in helping us to live longer?
- Metformin — miracle youth drug or a lot of hype?
- Of the seven kinds of cell damage that constitute aging, which are we gaining on with the current research?
- And which is the most challenging?
Dr. Aubrey de Grey is a biomedical gerontologist who researched the idea for and founded the SENS Research Foundation. SENS stands for “Strategies for Engineered Negligible Senescence,” an idea that Aubrey outlined in his 2007 book, Ending Aging. Aubrey has a BA in Computer Science and a Ph.D. in Biology from the University of Cambridge. He is Editor-in-Chief of Rejuvenation Research, is a Fellow of both the Gerontological Society of America and the American Aging Association, and sits on the editorial and scientific advisory boards of numerous journals and organizations. He is also a contributor to our book Visions for a World Transformed.